One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
Learn more: Researchers Computationally Find the Needle in a Haystack to Treat Rare Diseases
The Latest on: Drug repositioning
[google_news title=”” keyword=”drug repositioning” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]via Google News
[/vc_column_text][/vc_column]
The Latest on: Drug repositioning
- Transdermal Drug Delivery Systems Market Strategies: How to Stay Competitive in 2024-2032on May 9, 2024 at 6:07 pm
Global Transdermal Drug Delivery Systems Market is valued approximately at USD 59.16 billion in 2022 and is anticipated to grow with a growth rate of more than 11.90% over the forecast period ...
- Repositioning legal services for optimal impact in the public sector (4)on May 6, 2024 at 10:31 pm
In this concluding part of the keynote address presented at the annual legal summit of the Legal Services Department of the Niger-Delta Development Commission, vital suggestions are made for ...
- 6 CPAP Alternatives For Sleep Apnea, According To Expertson April 29, 2024 at 11:49 pm
There are two types of devices: mandibular repositioning mouthpieces ... Meanwhile, eXcite OSA, a device approved by the U.S. Food and Drug Administration (FDA), features a mouthpiece that ...
- Algorae harnessing AI to meet acute medical needson April 29, 2024 at 4:54 am
AlgoraeOS will utilise AI capabilities to connect previously disconnected data to assess drugs and molecules for potential repositioning into new drug candidates to meet medical needs. A primary ...
- Repositioning Therapeutic Cancer Vaccines in the Dawning Era of Potent Immune Interventionson April 26, 2024 at 5:00 pm
[82] CML patients on chronic treatment with the tyrosine kinase inhibitor imatinib mesylate (Gleevec®), responding to this drug, were vaccinated and monitored using the bcr/abl marker ...
- What to Do About Your Bunionson April 24, 2024 at 6:50 am
most of which involve cutting and repositioning the bone at the base of the big toe. Lapiplasty—the procedure Leonard had in Missouri—is a newer technique approved by the U.S. Food and Drug ...
- What Is Drug Repurposing And Why Is It A Game-Changer In Regenerative Medicine?on April 23, 2024 at 6:58 pm
or drug repositioning, involves the investigation of existing drugs developed for one purpose and repurposing them to treat different medical conditions. "This approach bypasses the lengthy and ...
- Drug Repurposing Market Projected to Reach USD 51.8 Billion by 2033, Driven by 4.5% CAGR | Market.uson April 22, 2024 at 4:59 pm
Drug repurposing, also known as drug repositioning or reprofiling, represents a transformative approach in the field of pharmaceutical research and development. This introduction explores the concept ...
- Repurposed drug shows promise against endometriosis-related pain in animal modelon March 18, 2024 at 2:16 pm
More information: Tomiko T. Oskotsky et al, Identifying therapeutic candidates for endometriosis through a transcriptomics-based drug repositioning approach, iScience (2024). DOI: 10.1016/j.isci.
- How digital twins of human cells are accelerating drug discoveryon April 11, 2022 at 9:28 am
Drug repositioning partnerships are one of several ways that researchers can work with DeepLife. The simplest option is the Datastore marketplace, which allows users to access organ omics atlases.
via Bing News